AstraZeneca Global R&D (Beijing) Co Ltd. has recently finalized its registration in the Beijing Economic-Technological Development Area (Beijing E-Town) marking a crucial advancement in their collaboration.

This achievement comes after the signing of a strategic earlier this year, paving the way for the establishment of their sixth global strategic research and development center in the region.

The company's business scope will include cell technology research and application, human gene diagnosis and therapeutic technology development, as well as human stem cell technology development and application.

As an important part of AstraZeneca's global strategic layout, leveraging Beijing's significant advantages in talent reserves, clinical resources, and approval processes, the company will play a key role in clinical research, injecting strong momentum into AstraZeneca's global drug development process and supporting the continuous innovation and development in the field of biomedicine.

The company is located in the BioPark, Beijing E-Town and is currently under construction. It is expected to be officially operational in 2026.